Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Aytu BioScience Inc
AYTU | US
2.10
USD-0.05
-2.33%
AYTU | US
About Aytu BioScience Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
2.10
Open
2.10
High
2.12
Low
2.04
Aytu Biopharma Inc. a commercial-stage pharmaceutical company focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers. The Consumer Health segment which consists of various consumer health products sell directly to consumers. It also offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. In addition the company provides Karbinal ER for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience Inc. and changed its name to Aytu Biopharma Inc. in March 2021. Aytu Biopharma Inc. was incorporated in 2015 and is headquartered in Englewood Colorado.
View LessAYTU | US
Risk
42.8
Sharpe
0.20
Luna's Score
36/100
Recommendation
Sell
Luna says (AYTU | US)
What's Working
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
45.1%1 month
42.8%3 months
37.2%6 months
47.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
9.96
Price to book
0.51
Debt to equity
0.55
Debt to assets
0.13
Ent. to EBITDA
1.14
Ent. to rev.
0.11
PEG
-
Other Fundamentals
EBITDA
6.11M
MarketCap
12.91M
MarketCap(USD)
12.91M
Div. yield
-
Op. margin
-4.45
Erngs. growth
-
Rev. growth
-41.50
Ret. on equity
-47.24
Short ratio
10.14
Short perc.
5.33
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.33
Range1M
0.65
Range3M
0.82
Volumes: Market Activity
Rel. volume
0.70
Price X volume
85.38K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.14 | - | Expensive |
| Ent. to Revenue | 0.11 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.51 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 37.18 | - | Lower Risk |
| Debt to Equity | 0.55 | -1.23 | Expensive |
| Debt to Assets | 0.13 | 0.25 | Cheaper |
| Market Cap | 12.91M | - | Emerging |
